Torrent Pharma's shares saw an increase after the USFDA completed its inspection at the company's manufacturing facility in Pithampur. The inspection, which took place in the September quarter, resulted in the issuance of a Form 483 with one observation.
This positive outcome has boosted investor confidence in Torrent Pharma, demonstrating trust in the company's compliance and operational standards.
The inspection was classified as 'Voluntary Action,' indicating that the USFDA did not find any significant violations that would require immediate regulatory action.